Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CITALOPRAM HYDROBROMIDE
Imbat Limited
N06AB04
CITALOPRAM HYDROBROMIDE
10 Milligram
Film Coated Tablet
Product subject to prescription which may not be renewed (A)
citalopram
Authorised
2009-04-24
_Page 1 of 2 _ PACKAGE LEAFLET: INFORMATION FOR THE USER CIPRAMIL ® 20MG FILM-COATED TABLETS Citalopram (as hydrobromide) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Cipramil is and what it is used for 2. Before you take Cipramil 3. How to take Cipramil 4. Possible side effects 5. How to store Cipramil 6. Further information 1. WHAT CIPRAMIL IS AND WHAT IT IS USED FOR HOW DOES CIPRAMIL WORK Cipramil is a Selective Serotonin Reuptake Inhibitor (SSRI) and belongs to a group of medicines known as antidepressants. These medicines help to correct certain chemical imbalances in the brain which are causing the symptoms of your illness. WHAT IS CIPRAMIL USED FOR Cipramil is used for the treatment of depression and when you feel better, to help prevent these symptoms recurring. Further, Cipramil is used for long-term treatment to prevent the occurrence of new depressive episodes in patients who have recurrent depression. Cipramil is also beneficial in relieving symptoms in patients prone to panic attacks. Your doctor, however, may prescribe Cipramil for another purpose. Ask your doctor if you have any questions about why Cipramil has been prescribed for you. 2. BEFORE YOU TAKE CIPRAMIL DO NOT TAKE CIPRAMIL if you are allergic (hypersensitive) to citalopram or any of the other ingredients of Cipramil at the same time as taking medication known as monoamine oxidase inhibitors (MAOIs) at the same time as taking pimozide if you were born with or have an episode of abnormal heart rhythm (seen at ECG; an examination to evaluate how the heart is functioning Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Cipramil 10mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains citalopram hydrobromide equivalent to 10 mg citalopram. Excipients: includes lactose For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet. _Product imported from the UK_ Round, white tablets with ‘CL’ embossed on one side and plain on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of depressive illness in the initial phase and as maintenance against potential relapse/recurrence. Cipramil is also indicated in the treatment of panic disorder with or without agoraphobia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS Depression Citalopram should be administered as a single oral dose of 20 mg daily. Dependent on individual patient response this may be increased to a maximum of 40 mg daily. Panic Disorder A single oral dose of 10 mg is recommended for the first week before increasing the dose to 20 mg daily. The dose may be further increased, up to a maximum of 40 mg daily dependent on individual patient response. OCD An initial dose of 20 mg daily recommended. Dependent on individual patient response, the dose may be increased to a maximum of 40 mg daily. Elderly patients (>65 years of age) For elderly patients the dose should be decreased to half the recommended dose, e.g. 10-20 mg daily. The recommended maximum dose for the elderly is 20 mg daily. Children & Adolescents (< 18 years) Cipramil should not be used in the treatment of children and adolescents under the age of 18 years (see section 4.4 Special warnings and precautions for use). Reduced hepatic function An initial dose of 10 mg daily for the first two weeks of treatment is recommended in patients with mild or moderate hepatic impairment. Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily. Caution and extra careful dose titration is advised in patients with severely reduced Read the complete document